188 related articles for article (PubMed ID: 36877089)
1. A cost-effectiveness analysis of first-line toripalimab plus chemotherapy in advanced nonsquamous non-small cell lung cancer in China.
Zheng Z; Zhu G; Cao X; Cai H; Zhu H
Expert Rev Clin Pharmacol; 2023 Mar; 16(3):267-273. PubMed ID: 36877089
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China.
Zhang M; Xu K; Lin Y; Zhou C; Bao Y; Zhang L; Li X
Front Immunol; 2023; 14():1169752. PubMed ID: 37313403
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers-Based Cost-Effectiveness of Toripalimab Plus Chemotherapy for Patients with Treatment-Naive Advanced Non-Small Cell Lung Cancer.
Zhang H; Li L; Feng L; Zhou Z; Zhang X; Feng J; Liu Q
Adv Ther; 2023 Nov; 40(11):4945-4956. PubMed ID: 37715852
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of toripalimab combined with chemotherapy in the treatment of non-small cell lung cancer.
Wang H; Long Y; Xu Y; Liao L; Zhou Y
Front Public Health; 2023; 11():1137255. PubMed ID: 37033059
[TBL] [Abstract][Full Text] [Related]
5. Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis.
Huo G; Liu W; Kang S; Chen P
Front Pharmacol; 2023; 14():1131219. PubMed ID: 36865925
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China.
Shang F; Zhang B; Kang S
Expert Rev Pharmacoecon Outcomes Res; 2023 Mar; 23(3):337-343. PubMed ID: 36655382
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China.
Zheng Z; Fang L; Cai H; Zhu H
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(6):683-690. PubMed ID: 37086175
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China.
Kang S; Wang X; Pan Z; Liu H
Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):285-292. PubMed ID: 37855081
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of sugemalimab in combination with chemotherapy as first-line treatment in Chinese patients with metastatic NSCLC.
Chen P; Li Y; Jing X; Chen J; Chen S; Yang Q
Lung Cancer; 2022 Dec; 174():157-164. PubMed ID: 36413882
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer.
Shu Y; Ding Y; Li F; Zhang Q
Int Immunopharmacol; 2023 Jan; 114():109589. PubMed ID: 36700770
[TBL] [Abstract][Full Text] [Related]
11. A Trial-Based Cost-Effectiveness Analysis of Bevacizumab and Chemotherapy Versus Chemotherapy Alone for Advanced Nonsquamous Non-Small-Cell Lung Cancer in China.
Li X; Li W; Hou L
Value Health Reg Issues; 2019 May; 18():1-7. PubMed ID: 30412913
[TBL] [Abstract][Full Text] [Related]
12. First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China.
Yang Z; Zhu Y; Xiang G; Hua T; Ni J; Zhao J; Lu Y; Wu Y; Chang F
Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1061-1067. PubMed ID: 33682554
[No Abstract] [Full Text] [Related]
13. Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and Cisplatin as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma.
Fang R; Wang S; Liu Y; Xu J
Adv Ther; 2023 Mar; 40(3):1019-1030. PubMed ID: 36622553
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC.
Wan N; Zhang TT; Hua SH; Lu ZL; Ji B; Li LX; Lu LQ; Huang WJ; Jiang J; Li J
Cancer Med; 2020 Mar; 9(5):1683-1693. PubMed ID: 31945265
[TBL] [Abstract][Full Text] [Related]
15. Toripalimab plus chemotherapy in American patients with recurrent or metastatic nasopharyngeal carcinoma: A cost-effectiveness analysis.
Lian D; Gan Y; Xiao D; Xuan D; Chen Y; Yang Y
Cancer Med; 2024 May; 13(10):e7243. PubMed ID: 38752448
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of toripalimab plus chemotherapy for advanced esophageal squamous cell carcinoma.
Xu K; Wu H; Zhou C; Bao Y; Yu M; Zhang L; Li X
Int J Clin Pharm; 2023 Jun; 45(3):641-649. PubMed ID: 36800145
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective.
Zhou K; Shu P; Zheng H; Li Q
Front Pharmacol; 2023; 14():1133085. PubMed ID: 37266153
[No Abstract] [Full Text] [Related]
19. Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis.
Liang X; Chen X; Li H; Liu X; Li Y
Front Public Health; 2023; 11():1054405. PubMed ID: 36923040
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China.
Rui M; Fei Z; Wang Y; Zhang X; Ma A; Sun H; Li H
J Med Econ; 2022; 25(1):618-629. PubMed ID: 35475459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]